Through collaborative endeavors involving researchers, clinicians, industry stakeholders and regulatory agencies, PSMA PET-CT holds promise to fundamentally transform the landscape of prostate cancer care, ushering in a new era of precision medicine and improved patient outcomes worldwide. The gene discussed is FOLH1; the disease is prostate cancer.